Trametinib-Resistant Melanoma Cells Displaying MITF

Paulina Koziej, Katarzyna Kluszczynska, Mariusz L Hartman, Malgorzata Czyz

Open access · goldAbstract read

In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it

0cells of the map it votes in

2citing papers in PubMed

0.8field-weighted citation impact, top 28% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Paulina KoziejDepartment of Molecular Biology of Cancer, Medical University of Lodz, 6/8 Mazowiecka Street, 92-215 Lodz, Poland.

Katarzyna KluszczynskaDepartment of Molecular Biology of Cancer, Medical University of Lodz, 6/8 Mazowiecka Street, 92-215 Lodz, Poland.ORCID 0000-0002-7290-1647

Mariusz L HartmanDepartment of Molecular Biology of Cancer, Medical University of Lodz, 6/8 Mazowiecka Street, 92-215 Lodz, Poland.ORCID 0000-0002-2231-3740

Malgorzata CzyzDepartment of Molecular Biology of Cancer, Medical University of Lodz, 6/8 Mazowiecka Street, 92-215 Lodz, Poland.ORCID 0000-0002-8279-4742

Medical University of Lodz · PL

Funding

Medical University of Lodz 503/1-156-01/503-11-001

6 · The paper itself

Abstract

Despite significant advances in targeted therapies against the hyperactivated BRAF

Indexed as

Interleukin-8MelanomaHumansMicrophthalmia-Associated Transcription FactorNerve Tissue ProteinsPhenotypeProto-Oncogene Proteins B-rafPyridonesPyrimidinonesReceptors, Nerve Growth FactorInterleukin-8Microphthalmia-Associated Transcription FactorMITF protein, humanNerve Tissue ProteinsNGFR protein, humanProto-Oncogene Proteins B-rafPyridonesPyrimidinonesReceptors, Nerve Growth Factortrametinibcancer cell plasticitydrug holidaydrug rechallengeIL-8melanomaMITFNGFRtargeted therapytrametinib resistance

Identifiers

PMID37175614

DOI10.3390/ijms24097891

PMCPMC10178474

OpenAlexW4367183154

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.